Search - tctmd.com

Displaying 141 - 160 of 211

Sort: Relevancy | Date

News Daily News

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

Salynn Boyles

December 15, 2014

News Daily News

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

December 14, 2014

News Daily News

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

Caitlin E. Cox

October 24, 2014

News Daily News

DCB在原发性病变中的表现比在再狭窄股腘动脉病变中更好

Caitlin E. Cox

October 24, 2014

News Daily News

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Caitlin E. Cox

October 24, 2014

Presentation TCT 2014

Status of DCB for PVD and Lessons Learned from the Recent FDA Panel

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Juan F. Granada

September 16, 2014

Presentation TCT 2014

The Emphatic Case for OPCs NOW for New DES Approval in the United States!

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Laura Mauri

September 16, 2014

Presentation TCT 2014

Device Approval Considerations (Preclinical and Clinical) for Bioresorbable Scaffolds: Update on FDA Regulatory Guidelines

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Kenya Brothers

September 16, 2014

Presentation TCT 2014

TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial

Presenter: Run-Lin Gao, Jochen Wöhrle, Bruno Scheller, Yelin Zhao

September 13, 2014

Presentation TCT 2014

DCB in BMS vs DES ISR: Insights from the RIBS Trials

Presenter: Run-Lin Gao, Jochen Wöhrle, Bruno Scheller, Fernando Alfonso

September 13, 2014

Presentation TCT 2014

Approach to In-Stent Restenosis in 2014: DCB or DES?

Presenter: Run-Lin Gao, Jochen Wöhrle, Bruno Scheller, Robert A. Byrne

September 13, 2014

Presentation TCT 2014

Acute Coronary Syndromes (Including STEMI)

Presenter: Azeem Latib, Ron Waksman, Ronald Caputo, Thomas A. Ischinger, Bruno Scheller

September 13, 2014

Presentation TCT 2014

Small Vessel, Diabetic, and Diffuse Disease

Presenter: Azeem Latib, Ron Waksman, Ronald Caputo, Thomas A. Ischinger, Paul JL Ong

September 13, 2014

Presentation TCT 2014

Bifurcations: Technical Approach and Clinical Results

Presenter: Azeem Latib, Ron Waksman, Ronald Caputo, Thomas A. Ischinger, Kenneth Chin

September 13, 2014

Presentation TCT 2014

DCB Plus Provisional Scaffold (BRS): Technique and Clinical Results

Presenter: Robert A. Byrne, Bruno Scheller, Francesco Liistro, Azeem Latib

September 13, 2014

Presentation TCT 2014

DCB Plus Adjunctive Stenting: Technique and Clinical Results

Presenter: Robert A. Byrne, Bruno Scheller, Francesco Liistro, Jochen Wöhrle

September 13, 2014

Presentation TCT 2014

DCB Only Followed by Provisional Stenting: Insights from BASKET-SMALL 2 Trial

Presenter: Robert A. Byrne, Bruno Scheller, Francesco Liistro, Raban Jeger

September 13, 2014

Presentation TCT 2014

Technique Strategy Selection: A Critical Review of International Consensus Group Position Papers

Presenter: Robert A. Byrne, Bruno Scheller, Francesco Liistro, Sahil A. Parikh

September 13, 2014

Presentation TCT 2014

DCB is a Useful Ancillary Tool but Unlikely to Become a Work-Horse Technology!

Presenter: Antonio Colombo

September 13, 2014

Presentation TCT 2014

The DCB-Only Approach Is Feasible: The Real Promise to Leave Nothing Behind!

Presenter: Franz X. Kleber

September 13, 2014

Advertisement

Drug-Coated Balloon Beats Angioplasty Alone in PAD Patients

OCTOPUS: Combo of BMS Plus Paclitaxel Balloon Appears Safe But May Be Outdated

Los BRF son Mejores en Lesiones De Novo que en Lesiones Femoropoplíteas Reestenóticas

DCB在原发性病变中的表现比在再狭窄股腘动脉病变中更好

DCBs Perform Better in De Novo Compared With Restenotic Femoropopliteal Lesions

Status of DCB for PVD and Lessons Learned from the Recent FDA Panel

The Emphatic Case for OPCs NOW for New DES Approval in the United States!

Device Approval Considerations (Preclinical and Clinical) for Bioresorbable Scaffolds: Update on FDA Regulatory Guidelines

TCT 267: Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-up of the PEPCAD China ISR Trial

DCB in BMS vs DES ISR: Insights from the RIBS Trials

Approach to In-Stent Restenosis in 2014: DCB or DES?

Acute Coronary Syndromes (Including STEMI)

Small Vessel, Diabetic, and Diffuse Disease

Bifurcations: Technical Approach and Clinical Results

DCB Plus Provisional Scaffold (BRS): Technique and Clinical Results

DCB Plus Adjunctive Stenting: Technique and Clinical Results

DCB Only Followed by Provisional Stenting: Insights from BASKET-SMALL 2 Trial

Technique Strategy Selection: A Critical Review of International Consensus Group Position Papers

DCB is a Useful Ancillary Tool but Unlikely to Become a Work-Horse Technology!

The DCB-Only Approach Is Feasible: The Real Promise to Leave Nothing Behind!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content